This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alphatec Spine Announces Fourth Quarter And Full Year 2010 Revenue And Financial Results

  • Annual GAAP revenue of $171.6 million; 42.3% growth over 2009; pro forma revenue of $182.9 million; 7.1% growth over 2009 and 8.3% growth on a constant-currency basis
  • Adjusted EBITDA of $18.9 million; 32.2% growth over 2009

CARLSBAD, Calif., Feb. 24, 2011 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today financial results for the fourth quarter and full year ended December 31, 2010.

2010 Performance Highlights
  • Positioned Alphatec as a global leader within the spine market.
  • Completed acquisition of Scient'x S.A.
  • Acquisition created global scale with sales in over 50 countries in all major markets.
  • Combined entity is the third-largest global pure-play spinal implant company.
  • Alphatec Spine products launched in all major European markets and several other major international markets.
  • Achieved significant revenue growth in key markets.
  • Achieved annual U.S. revenue of $119.9 million, representing 14.7% year-over-year growth on a GAAP basis, and 6.1% year-over-year growth on a pro forma basis.
  • With expanded European product distribution, achieved annual Europe revenue of $24.2 million, representing more than 490% year-over-year growth on a GAAP basis, and 16.9% year-over-year growth on a pro forma basis.
  • Achieved annual Asia revenue of $20.0 million, representing 66.8% year-over-year growth on a GAAP basis, and 16.8% year-over-year growth on a pro forma basis.
  • Enhanced product offerings in the Biologics market.
  • Launched PureGen TM Osteoprogenitor Cell Allograft in September 2010.
  • Established Biologics Division with dedicated sales specialists and biologics experts to drive biologics product adoption and provide support for the surgeon community with respect to the Company's biologics products.
  • Enhanced product offerings in the Aging Spine and MIS markets.
  • All proprietary aging spine products, including Osseofix ®, OsseoScrew ®, and Helifix TM have been launched in Europe.
  • OsseoFix has been used in approximately 1,900 patients and OsseoScrew has been used in approximately 200 patients in Europe.
  • Illico SE ® Percutaneous MIS Screw System, as well as Solus TM Locking ALIF System, have been launched in Europe.
  • MIS revenues for full year 2010 increased more than 480% from full year 2009.

Dirk Kuyper, the Company's President and Chief Executive Officer, stated: "I am proud of the performance and results that our company delivered in 2010. We have successfully positioned Alphatec Spine as a leader within the spine market, with a broad and expanded global reach, integrated R&D and manufacturing and continued focus on both the core spine market as well as differentiated technologies in Aging Spine, MIS and Biologics." Mr. Kuyper continued, "As we enter 2011, we remain confident in our ability to grow faster than the overall spine market and to drive towards our goal of being the leading global pure-play spine company. We have the team, the products and the strategic plan to achieve long-term revenue growth, profitability, and generation of free cash flow."

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.33 -1.00%
FB $100.31 -0.68%
GOOG $676.72 -1.10%
TSLA $153.08 6.50%
YHOO $26.46 -2.40%


Chart of I:DJI
DOW 15,578.62 -336.12 -2.11%
S&P 500 1,819.43 -32.43 -1.75%
NASDAQ 4,237.4920 -46.10 -1.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs